Any fears that COVID-19 might stem the flow of new drug approvals in 2020, depleting or diverting resources at regulatory agencies and their pharmaceutical clients, appear largely premature.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, launch readiness, EMA Approvals, FDA Approvals
The widespread disruption caused by the coronavirus pandemic is forcing pharmaceutical companies to think more creatively and flexibly about how their business model can accommodate new restraints such as home working, restricted face-to-face contact, travel bans, supply-chain bottlenecks, stalled clinical-trial recruitment, diverted healthcare budgets, closer scrutiny of drug reimbursement, and depleted staffing at regulatory agencies. Digital technology will be a crucial tool in addressing these challenges and softening the pandemic’s multiple potential impacts on drug launches.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #covid-19, coronavirus
One notable characteristic of the launch readiness landscape as we settle into 2020 is the lower volume of innovative drugs entering the marketplace. The record number of approvals granted in 2018 by the two most influential agencies, the US Food and Drug Administration and the European Medicines Agency, did not hold up in 2019.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management
For all its reliance on innovation as a business driver, pharmaceuticals is a traditionally conservative industry that advances by small and careful steps. As we map out some of the dominant pharma trends for 2020, perhaps we should also reflect on what ‘innovation’ actually means, what its value is, and what it costs.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #2019 Pharma Trends
As we inch warily or rush enthusiastically into another year against a backdrop of political turmoil and business uncertainty in major markets, it is time to look at the prevailing 2019 pharmaceutical industry trends and what they might mean for companies launching new medicines, negotiating market access barriers, or simply trying to do what they do better. Inevitably, the US is in the thick of the action. But there are many other important 2019 pharma trends, both national and global, that will set the pace for industry throughout what promises to be another dynamic and challenging year.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #2019 Pharma Trends
